Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Yum China Holdings Inc — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Yum China Holdings Inc trades at $43.53 (market cap $14.46B). The key difference: Yum China Holdings Inc is far larger — about 3× Travere Therapeutics Inc. Common Stock's market cap, and Yum China Holdings Inc pays a 2.71% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Yum China Holdings Inc for 77 Days on average.
| TVTX | YUMC | |
|---|---|---|
Market Cap | $4.88B | $14.46B |
Volume | 1,668,577 | 996,391 |
Sector | Health | Consumer Cyclical |
52-Week High | $67.52 | $57.95 |
52-Week Low | $26.79 | $39.98 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $5.01B | $15.37B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
YUMC trades at $43.11, up 0.63% today, with a bullish technical signal and strong analyst support (14 Buy, 5 Hold). The stock shows consistent earnings beats, with Q2 2026 EPS of $0.70 surpassing the $0.67 estimate. Revenue grew to $11.80B in 2025, and net income reached $929M. Recent corporate actions include a $0.29 dividend and the acquisition of Pizza Hut brand ownership in Mainland China, enhancing long-term growth prospects.
YUMC presents a favorable investment case with solid fundamentals, reasonable valuation (P/E 15.69), and positive earnings momentum. Key risks include competitive pressures in China's restaurant sector and macroeconomic sensitivity. Wall Street's average price target implies a 25.6% upside, supporting a bullish outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
